The Data Management and Biostafistics Core (DMBC) will serve as a resource and collaborator for all projects and cores related to this program project. Specifically the DMBC will: (1) consult on the design of all projects and in the application of appropriate stafistical and methodological techniques;(2) lead and collaborate in data analysis and report preparafion for all cores and projects, especially in the analysis of associafions among longitudinal growth/decline patterns of all disease markers across the individual projects;(3) coordinate and implement participant scheduling program across all projects and cores;(4) confinue our collaborafion with the WU Center for Biomedical Informafics (CBMI) to complete the transition to our bioinformatics platforms, make data collected by ACS cores and projects available to all ACS invesfigators, and insure the quality control of all analysis data sets for publications;(5) collaborate in the design of all forms to be used;(6) develop, apply, and implement stafisfical data analysis techniques appropriate for addressing the scientific aims of the program project.

Public Health Relevance

The Data Management and Biostafistics Core (DMBC) provides design, analyses, and data management resources to support all the ACS projects and cores. The relevance of the DMBC is that ACS addresses crucial public health questions to identify the eariiest possible biomarker changes for Alzheimer's disease and dementia so that prevention and/or treatment can be started early.

Agency
National Institute of Health (NIH)
Institute
National Institute on Aging (NIA)
Type
Research Program Projects (P01)
Project #
2P01AG026276-06A1
Application #
8287319
Study Section
Special Emphasis Panel (ZAG1-ZIJ-4 (01))
Project Start
2011-09-30
Project End
2016-08-31
Budget Start
2011-09-30
Budget End
2012-08-31
Support Year
6
Fiscal Year
2011
Total Cost
$81,190
Indirect Cost
Name
Washington University
Department
Type
DUNS #
068552207
City
Saint Louis
State
MO
Country
United States
Zip Code
63130
Liao, Fan; Li, Aimin; Xiong, Monica et al. (2018) Targeting of nonlipidated, aggregated apoE with antibodies inhibits amyloid accumulation. J Clin Invest 128:2144-2155
Yan, Qi; Nho, Kwangsik; Del-Aguila, Jorge L et al. (2018) Genome-wide association study of brain amyloid deposition as measured by Pittsburgh Compound-B (PiB)-PET imaging. Mol Psychiatry :
Strain, Jeremy F; Smith, Robert X; Beaumont, Helen et al. (2018) Loss of white matter integrity reflects tau accumulation in Alzheimer disease defined regions. Neurology 91:e313-e318
Li, Zeran; Del-Aguila, Jorge L; Dube, Umber et al. (2018) Genetic variants associated with Alzheimer's disease confer different cerebral cortex cell-type population structure. Genome Med 10:43
Schindler, Suzanne E; Sutphen, Courtney L; Teunissen, Charlotte et al. (2018) Upward drift in cerebrospinal fluid amyloid ? 42 assay values for more than 10 years. Alzheimers Dement 14:62-70
Sato, Chihiro; Barthélemy, Nicolas R; Mawuenyega, Kwasi G et al. (2018) Tau Kinetics in Neurons and the Human Central Nervous System. Neuron 98:861-864
Babulal, Ganesh M; Chen, Suzie; Williams, Monique M et al. (2018) Depression and Alzheimer's Disease Biomarkers Predict Driving Decline. J Alzheimers Dis 66:1213-1221
Millar, Peter R; Balota, David A; Bishara, Anthony J et al. (2018) Multinomial models reveal deficits of two distinct controlled retrieval processes in aging and very mild Alzheimer disease. Mem Cognit 46:1058-1075
Gangishetti, Umesh; Christina Howell, J; Perrin, Richard J et al. (2018) Non-beta-amyloid/tau cerebrospinal fluid markers inform staging and progression in Alzheimer's disease. Alzheimers Res Ther 10:98
Vlassenko, Andrei G; Gordon, Brian A; Goyal, Manu S et al. (2018) Aerobic glycolysis and tau deposition in preclinical Alzheimer's disease. Neurobiol Aging 67:95-98

Showing the most recent 10 out of 352 publications